



*Improving the quality of life for people in pain through novel,
cost effective pain assessment tools*

ASX release: 26th September 2017

ePAT Technologies Limited
ABN 21 146 035 127
Suite 401, 35 Lime Street, Sydney, NSW, 2000
Registered Office: Suite 5, 95 Hay Street Subiaco WA 6008
Phone +61 8 9388 8290

ePAT accelerates commercialisation at National Alzheimer's Conference Melbourne 17th- 20th October

- **Dementia Support Australia and ePAT to co-host ePAT App launch event targeted to dementia care and aged care specialists**
- **ePAT's Mustafa Atee presents on the ePAT App during a clinical session**
- **ePAT to have strong personnel and product presence throughout the conference**

During 17th-20th October 2017 up to 800 dementia and aged care specialists throughout Australia will be attending the National Alzheimer's "*Be the Change*" conference in Melbourne.

On the evening of October 17th, ePAT and Dementia Support Australia (DSA) are co-hosting a launch event for selected delegates entitled "*An innovative collaboration gives voice to those living with Dementia*". Associate Professor Colm Cunningham of HammondCare and Philip Daffas of ePAT will be amongst a number of speakers to demonstrate how the ePAT and DSA collaboration can empower carers of people with dementia to better assess and manage pain improving people's quality of life.

ePAT's Scientific Officer, Mustafa Atee will be presenting "*The electronic Pain Assessment Tool (ePAT): A novel pain scale for patients with dementia*" on 18th October. During this 30-minute session, Mustafa will report on the clinical value and utility of the ePAT App for people with dementia to the conference delegates.

Throughout the conference ePAT will have a strong people presence and exhibit in the trade show to engage with and present the ePAT App to the Australian aged care and dementia care community. A number of key meetings with aged care management are already scheduled.

Philip Daffas, ePATs' Managing Director said "Taking an active participation at this conference is another positive step in our commercialisation strategy. ePAT is uniquely positioned as a world first regulatory cleared pain assessment App, now recognised by the dementia healthcare professionals. Moreover, following a successful capital raising, we now have market credibility and funding in place to build a sustainable business model and revenue stream in Australia and into international markets over the next year".

ePAT and DSA Collaboration:

As reported previously, the DSA agreement is a key business milestone as it provides ePAT with two core benefits. It is a first commercial agreement with a recognised Australian government sponsored body that has been tasked with the goal of improving the quality of life for people with dementia. This provides great credibility to the ePAT App.


Secondly, DSA's 150 consultants across Australia will be using the ePAT App as a baseline tool to assess pain in up to 5000 people with dementia each year who reside within the 1500 aged care and home care providers in Australia. The consultation typically lasts for a 4-6 week period dependent on the severity of the case. At the conclusion of the DSA consultation, the aged care or community care group will have been made aware of the ePAT App and will have the option to continue to use the ePAT App for their residents for the longer term through a separate license negotiated with ePAT.

The ePAT/DSA agreement is designed to help fast track the market awareness and empower take up of the ePAT App with carers of the 400,000 people with dementia in Australia. For further information about DSA, go to www.dementia.com.au


About ePAT:

ePAT Technologies Limited is an Australian-based company that has developed mobile medical applications to provide pain assessment for individuals who are unable to communicate verbally with their carers.

ePAT's technology, a mobile application, the ePAT App*, uses the cameras in smartphones and tablets to capture a brief video of the person, which is analysed in real time using facial emotion software to detect the presence of facial micro-expressions that are indicative of the presence of pain.



The ePAT App six domains of pain assessment that calculates pain severity score



ePAT artificial intelligence assesses facial micro-expressions that are indicative of the presence of pain

This data is then combined with other indicators of pain, such as vocalisations, behaviours and movements captured through the ePAT App to calculate a pain severity score. Due to its ease of use and its reproducibility, the ePAT App will be able to be used in the first instance to detect and measure a person's pain, and further measurements can be used to monitor the effectiveness of pain management.

The ePAT App will be rolled out globally in two phases: first, the ePAT App for dementia with people who are unable to communicate effectively, and second, the ePAT App for children who have not yet learnt to speak.

*The ePAT App is a Class 1 Medical Device that has TGA (Australia) and CE mark (Europe Economic Area) regulatory clearance.

For further information, please contact:

Ian Hobson
Company Secretary
Tel: +61 8 9388 8290

Philip Daffas
Managing Director
Tel: +61 406-537-235